Related content

The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid

By Donald P.   Parkin D.   Seifart H.   Schaaf H.   Helden P.   Werely C.   Sirgel F.   Venter A.   Maritz J.  

European Journal of Clinical Pharmacology, Vol. 63, Iss. 7, 2007-07 ,pp. : 633-639

Springer Publishing Company

Access to resources Recommend Favorite

Arylamine N-acetyltransferase 2 slow acetylator polymorphisms in unrelated Iranian individuals

By Bakayev Valery   Mohammadi Forozan   Bahadori Moslem   Sheikholslami Mariam   Javeri Arash   Masjedi Mohammad   Velayati Ali  

European Journal of Clinical Pharmacology, Vol. 60, Iss. 7, 2004-09 ,pp. : 467-471

Springer Publishing Company

Access to resources Recommend Favorite

Refinement of the prediction of N-acetyltransferase 2 (NAT2) phenotypes with respect to enzyme activity and urinary bladder cancer risk

By Selinski Silvia   Blaszkewicz Meinolf   Ickstadt Katja   Hengstler Jan   Golka Klaus  

Archives of Toxicology, Vol. 87, Iss. 12, 2013-12 ,pp. : 2129-2139

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacogenomics of Arylamine N-acetyltransferase

By  

Current Pharmacogenomics, Vol. 2, Iss. 3, 2004-09 ,pp. : 219-231

Bentham Science Publishers

Access to resources Recommend Favorite

The effect of Shoseiryuto, a traditional Japanese medicine, on cytochrome P450s, N-acetyltransferase 2 and xanthine oxidase, in extensive or intermediate metabolizers of CYP2D6

By Nakao Masashi   Muramoto Yousuke   Hisadome Motoko   Yamano Naoko   Shoji Mami   Fukushima Yumi   Saruwatari Junji   Nakagawa Kazuko  

European Journal of Clinical Pharmacology, Vol. 63, Iss. 4, 2007-04 ,pp. : 345-353

Springer Publishing Company

Access to resources Recommend Favorite